SEMA4D and juvenile Huntington disease: In addition, pepinemab, a humanised anti-SEMA4D monoclonal antibody, has been evaluated in several clinical trials, including a Phase I trial in patients with multiple sclerosis (NCT01764737) and a Phase II trial in Huntington’s disease (NCT02481674).